Cleo Strengthens Cash Position with $1.7m R&D Tax Refund
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Following this refund, the company reports a strong cash balance, enabling it to pursue key milestones, including a pivotal clinical trial and FDA submission for its Pre-Surgical Ovarian Cancer Test. The CEO emphasized that this financial boost supports their critical phase of development and commercialization of technology aimed at transforming ovarian cancer detection.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from CLEO Diagnostics
- CLEO Appoints First Key Opinion Leader to Support US Market
- CLEO Significantly Expands Addressable Market
- CLEO Successfully Completes Stage 1 MDSAP Audit
- Cleo Receives Positive FDA Feedback
- Appendix 4E and 2025 Annual Report
Later from CLEO Diagnostics
- Trading Halt
- CLEO Raises $5m to Support U.S. Market Launch
- Quarterly activities and cashflow report
- CLEO Confirms Next-Gen Platform for Ovarian Cancer Test
- Appendix 4D and Half Yearly Accounts
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics